Navigation Links
Waters SYNAPT HDMS and Xevo TQ MS Recognized for Mass Spectrometry Innovation by Industry Experts
Date:8/19/2008

Frost & Sullivan and Strategic Directions International Magazine Identify

Waters Mass Spectrometers as Technology Leaders

MILFORD, Mass., Aug. 19 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT) today announced that Waters(R) SYNAPT(TM) High Definition MS(TM) (HDMS(TM)) System was recognized by Frost & Sullivan for a Product Innovation of the Year award, and Strategic Directions International's Instrument Business Outlook (IBO) selected the Xevo(TM) TQ MS System as the Best New Product at the 2008 American Society of Mass Spectrometry (ASMS) annual meeting.

"We are appreciative of the due diligence from both Frost & Sullivan and IBO, and are honored by their respective recognition in evaluating Waters SYNAPT HDMS and Xevo TQ MS," said Brian W. Smith, Vice President, Mass Spectrometry Operations, for the Waters Division. "Waters mass spectrometry is experiencing significant momentum in the marketplace. Our scientists have developed novel innovations and the beneficiaries have been our customers who are realizing new levels of success in reaching their own goals and achievements."

In 2006, Waters introduced the SYNAPT HDMS System, the first mass spectrometry (MS) system to leverage high-efficiency ion mobility-based measurements and to advance research in proteomics, structural biology and small molecule experiments. "This unique combination of technologies allow scientists to differentiate samples by their size, shape, and charge, as well as mass, which has enabled the separation, detection, and characterization of components not possible with conventional mass spectrometry," said Frost & Sullivan Research Analyst, Lakshman Koundinya.

The Xevo TQ MS System, an advanced tandem quadrupole mass spectrometer designed to deliver unrivalled performance and functionality, uses innovative IntelliStart(TM) and ScanWave(TM) technologies to deliver versatility and advanced quantitative capability to a broader range of scientists. "The Xevo's novel collision cell design enables it to operate in T-Wave(TM) mode or in Waters' more recently developed ScanWave mode. T-Wave has the effect of significantly improving the fast scanning abilities of tandem MS," wrote IBO. "Perhaps the more interesting capability is the ScanWave mode of the collision cell, which helps Xevo to significantly increase the signal intensity of both parent and product ion spectra."

The following URL links are available for more information on:

-- Waters SYNAPT HDMS -- http://www.waters.com/waters/nav.htm?cid=514457

-- Waters Xevo TQ MS -- http://www.waters.com/waters/nav.htm?cid=10064408

-- Frost & Sullivan Best Practices Awards -- http://www.awards.frost.com -- Instrument Business Outlook magazine -- http://www.strategic- directions.com/apps/ibo/index.cfm?action=detail&page=ibo&sdi=-1933506781 (due to the length of the URL, please copy and paste into web browser)

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

About Strategic Directions International

Strategic Directions International (SDi) is the world leader in business intelligence for analytical and life science instruments, equipment and related products. SDi products and services are recognized as the standard reference source used by corporate executives, business development personnel, equity and financial analysts, regulatory agencies, technology developers and the scientific/analytical instrument community at large. Established in 1981, SDi is headquartered in Los Angeles with a branch office in the UK. For more information about SDi, visit http://www.strategic-directions.com.

About Waters Corporation (http://www.waters.com)

Waters Corporation creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.47 billion in 2007 and 5,000 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, The Science of What's Possible, SYNAPT, High Definition MS, HDMS, Xevo, ScanWave, Intellistart, and T-Wave are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

Contact: Brian J. Murphy

Waters Corporation

Public Relations Manager

508-482-2614

Brian_J_Murphy@waters.com


'/>"/>
SOURCE Waters Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Frost & Sullivan Recognizes Waters Corporation for Its Pioneering, High Customer Value Analytical Instrumentation Product, SYNAPT HDMS
2. Waters Offers U.S. Water Authorities Complimentary Drinking Water Testing for the Presence of Pharmaceuticals
3. Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008
4. Vanderbilt University Medical Center and Waters Collaborate on Tissue Imaging Research Using SYNAPT HDMS
5. 2007: A Watershed Year for Lupus Research and Education
6. Extracts of catfish caught in polluted waters cause breast cancer cells to multiply
7. Waters Corporation Receives Market Leadership and Product Innovation Awards
8. Out of the woods: Physicians get urban disaster training in forests, gorges and waters
9. Covance Recognized for Outstanding Performance by Merck & Co., Inc.
10. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
11. Nationally Recognized Pediatric Healthcare System Chooses PureWellness for Employee Wellness Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... campaign returns for a third time to shed lights on the variety of topics ... and inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign aimed at ... stories, courtesy of awareness-driven celebrities and thought leaders. It also provides insight to ... industry leaders such as Bioness. , As patients feel increasingly concerned about ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... interest stories, courtesy of leaders in the nursing and health care industry. It ... leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... the necessity of health literacy within the technology advancement of diagnostic imaging. According to a ... majority of oncology patients undergo imaging screenings without understanding the nuanced risks associated with ... ... ... Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... , May 26, 2016 ... market growth is the emergence of new treatments. Cardax, ... therapies for osteoarthritis treatment. The therapy is expected to ... Arthritis Research UK is conducting studies to develop new ... study, where the genes involved in osteoarthritis are being ...
Breaking Medicine Technology: